5月19日，诺诚健华（09969）盘中股价一度上涨超5%，截至发稿涨幅为2.21%，报10.14港元。公司核心产品奥布替尼一季度销售收入达3.11亿元，同比增长89.22%。浦银国际指出，其销售表现好于预期，主要受益于MZL适应症放量、市场份额提升及用药时长延长。管理层将奥布替尼全年收入增速从30%上调至35%，预计MZL对收入贡献占比将从2024年的30%提升至2025年的50%。
Source Link5月19日，诺诚健华（09969）盘中股价一度上涨超5%，截至发稿涨幅为2.21%，报10.14港元。公司核心产品奥布替尼一季度销售收入达3.11亿元，同比增长89.22%。浦银国际指出，其销售表现好于预期，主要受益于MZL适应症放量、市场份额提升及用药时长延长。管理层将奥布替尼全年收入增速从30%上调至35%，预计MZL对收入贡献占比将从2024年的30%提升至2025年的50%。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.